4 Healthcare Stock Stories Prescribed for Investors on Tuesday

Vivus (NASDAQ:VVUS) Closing price $10.63

On Tuesday, Vivus reported that it entered into a $110 million non-equity financing with an investment fund managed by Pharmakon Advisors. Through the terms, the firm will make an initial draw of $50 million and will have the option to draw a further $60 million at any time before December 31, 2013. Vivus will make no payments for the first year, and repayments will commence in the second quarter of 2014 and end in the second quarter of 2018, and will be based on scheduled quarterly amounts.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

VVUS

Omeros Corporation (NASDAQ:OMER): Closing price $4.09

On Tuesday, Omeros reported positive data from the multiple-ascending-dose portion of its Phase 1 clinical trial evaluating OMS824, the lead compound in the firm’s phosphodiesterase 10 program. Along with these data and the previously announced successful single-ascending-dose portion of this clinical trial, Omeros is moving OMS824 towards a Phase 2 clinical program. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain connected with a wide range of diseases that affect cognition, including Huntington’s disease and schizophrenia.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

OMER

Pfizer (NYSE:PFE): Closing price $28.60

The FDA has added Pfizer’s tuberculosis treatment rifampin to its list of drugs in short supply, marking the most recent in a growing number of spottily available TB medications. The agency noted in a post on its website Monday that the injectible antibiotic will be in short supply until the end of June, blaming the cause of the shortage to manufacturing delay, according to Reuters. Rifampin is one of the most potent and widely used TB drugs, and its shortage comes during an increased prevalence of the disease worldwide, although TB rates in the United States dropped to an all-time low in 2012.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

PFE

BioDelivery Sciences International (NASDAQ:BDSI): Closing price $4.14

BioDelivery announced Tuesday that it has entered into a worldwide licensing agreement with privately-held Arcion Therapeutics, through which the former will develop and commercialize topical clonidine gel (formerly ARC4558) for the treatment of painful diabetic neuropathy and potentially other indications. Within the terms of the agreement, BioDelivery will make an upfront payment of $2 million to Arcion in the form of unregistered shares of its common stock.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BDSI

Don’t Miss: Will Dendreon Continue to Plummet?